News

MMJ BioScience has filed a patent invention with the U.S. Patent and Trademark Office for its part-cannabinoid treatment for patients with cannabinoid-responsive diseases, including Huntington’s disease and multiple sclerosis. According to the announcement by MMJ BioScience — an affiliate of MMJ International Holdings, the patent will protect…

Huntington’s disease (HD) patients respond to endurance training much like anyone else, by increasing muscular energy metabolism, say Swiss researchers who suggest such training might help delay muscular dysfunction in patients. Their study, “Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients,” appeared in the…

Researchers found biomarkers — molecules with elevated levels — in people who carry the Huntington’s disease (HD) gene who have not yet shown symptoms of the disease. These markers may allow for the testing of new treatments before the onset of Huntington’s in susceptible individuals. The study, “MicroRNAs in…

Researchers have found that bexarotene, an existing, approved drug used to treat cancer, may also be an effective therapy for Huntington’s disease. The study, “PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis,” appeared in the journal Science Translational Medicine. Researchers used…

People with Huntington’s disease in the U.K. are pushing for more open communication regarding assisted dying between clinicians, patients, and their families, a small research study indicates. A first-of-its-kind study in the United Kingdom, where assisted dying is illegal, looked into the attitudes of people with the debilitating disease, which…

Aberrant metabolism of urea is a potential first event promoting Huntington’s disease (HD), a study with a sheep model and human brain samples showed. The findings suggest that lowering brain levels of urea is a potential therapeutic avenue for HD. The report “Brain urea increase is an early Huntington’s…

The chemical compound manganese (Mn) has been reported to take part in the underlying mechanism of Alzheimer’s disease. However, little is known about its involvement in the development of other neurodegenerative diseases. In the study titled “Manganese in manganism, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and…

Roche will now be responsible for the development and marketing of Ionis Pharmaceuticals’ IONIS-HTTRx after exercising its option to license the investigational drug, designed to treat Huntington’s disease (HD). This move follows highly promising results from a Phase 1/2a clinical trial. The randomized, double-blind, placebo-controlled trial (NCT02519036) tested…

Embryonic stem cells have been seen as a potential therapeutic strategy for several diseases. However, the manipulation of these cells has been a challenge for scientists due to their complex regulatory systems. In a study published in Nature Communications a team led by researchers at the Cologne Cluster…

A poorly active enzyme called aconitase 2 (Aco2), found at low levels in cells, can be a marker of the mitochondrial dysfunction linked to Huntington’s disease and its progression, an early study reports. The study, “Altered Aconitase 2 Activity in Huntington’s Disease Peripheral Blood Cells and Mouse…